US Patent and Trademark Office Issues Key Patent For OncoGenex’s OGX-011

US Patent and Trademark Office (PTO) has issued US Patent Number 7,569,551 entitled Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides, on the method of using OncoGenex’s OGX-011, to treat certain cancers.

The patent, licensed from the University of British Columbia, includes coverage for the method of treating cancers that express the protein clusterin using OGX-011 or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

Scott Cormack, president and CEO of OncoGenex, said: The issuance of this patent expands our property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer. Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011.